Menglu Wang1,2, Shi Chen1,2, Yingdong He3,4, Minghui Zhao5, Huixia Yang1,2, Qian Chen1,2. 1. Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, 100034, People's Republic of China. 2. Beijing Key Laboratory of Maternal-Fetal Medicine of Gestational Diabetes Mellitus, Beijing, People's Republic of China. 3. Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, 100034, People's Republic of China. dongyinghe1234@163.com. 4. Beijing Key Laboratory of Maternal-Fetal Medicine of Gestational Diabetes Mellitus, Beijing, People's Republic of China. dongyinghe1234@163.com. 5. Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, People's Republic of China.
Abstract
OBJECTIVE: The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD). METHODS: The clinical data of pregnant women with CKD were retrospectively analyzed at Peking University First Hospital between January 2013 and January 2020. Among 287 pregnant women with stage 1-2 CKD, 63 patients who were treated with LDA were included in study group 1, and 63 patients who were not treated with aspirin were allocated to control group 1. Among 41 pregnant women with stage 3-5 CKD, 22 patients who were treated with LDA were included in study group 2, and 19 patients were allocated to control group 2. Pregnancy outcomes of the patients with stage 1-2 and stage 3-5 CKD who received LDA during pregnancy and those who did not were compared. RESULTS: No significant difference was observed in the incidence of preeclampsia or severe preeclampsia between study and control group 1. The patients in study group 2 had a lower incidence of severe preeclampsia than those in control group 2 (3/22 [13.6%] vs. 8/19 [42.1%], P = 0.04). Among the patients with stage 3-5 CKD, LDA therapy during pregnancy was associated with a lower risk of severe preeclampsia (odds ratio = 0.22, 95% confidence interval: 0.074-0.993; P = 0.049). CONCLUSIONS: LDA therapy during pregnancy can reduce the risk of severe preeclampsia in patients with stage 3-5 CKD. Prospective studies are needed to further explore the preventive effects of aspirin on preeclampsia in patients with stage 1-2 CKD.
OBJECTIVE: The objective of the study was to investigate the effects of low-dose aspirin (LDA) during pregnancy on the prevention of preeclampsia in patients with chronic kidney disease (CKD). METHODS: The clinical data of pregnant women with CKD were retrospectively analyzed at Peking University First Hospital between January 2013 and January 2020. Among 287 pregnant women with stage 1-2 CKD, 63 patients who were treated with LDA were included in study group 1, and 63 patients who were not treated with aspirin were allocated to control group 1. Among 41 pregnant women with stage 3-5 CKD, 22 patients who were treated with LDA were included in study group 2, and 19 patients were allocated to control group 2. Pregnancy outcomes of the patients with stage 1-2 and stage 3-5 CKD who received LDA during pregnancy and those who did not were compared. RESULTS: No significant difference was observed in the incidence of preeclampsia or severe preeclampsia between study and control group 1. The patients in study group 2 had a lower incidence of severe preeclampsia than those in control group 2 (3/22 [13.6%] vs. 8/19 [42.1%], P = 0.04). Among the patients with stage 3-5 CKD, LDA therapy during pregnancy was associated with a lower risk of severe preeclampsia (odds ratio = 0.22, 95% confidence interval: 0.074-0.993; P = 0.049). CONCLUSIONS: LDA therapy during pregnancy can reduce the risk of severe preeclampsia in patients with stage 3-5 CKD. Prospective studies are needed to further explore the preventive effects of aspirin on preeclampsia in patients with stage 1-2 CKD.
Authors: Mark A Brown; Laura A Magee; Louise C Kenny; S Ananth Karumanchi; Fergus P McCarthy; Shigeru Saito; David R Hall; Charlotte E Warren; Gloria Adoyi; Salisu Ishaku Journal: Hypertension Date: 2018-07 Impact factor: 10.190
Authors: Liona C Poon; Andrew Shennan; Jonathan A Hyett; Anil Kapur; Eran Hadar; Hema Divakar; Fionnuala McAuliffe; Fabricio da Silva Costa; Peter von Dadelszen; Harold David McIntyre; Anne B Kihara; Gian Carlo Di Renzo; Roberto Romero; Mary D'Alton; Vincenzo Berghella; Kypros H Nicolaides; Moshe Hod Journal: Int J Gynaecol Obstet Date: 2019-05 Impact factor: 3.561
Authors: Daniel L Rolnik; David Wright; Liona C Poon; Neil O'Gorman; Argyro Syngelaki; Catalina de Paco Matallana; Ranjit Akolekar; Simona Cicero; Deepa Janga; Mandeep Singh; Francisca S Molina; Nicola Persico; Jacques C Jani; Walter Plasencia; George Papaioannou; Kinneret Tenenbaum-Gavish; Hamutal Meiri; Sveinbjorn Gizurarson; Kate Maclagan; Kypros H Nicolaides Journal: N Engl J Med Date: 2017-06-28 Impact factor: 91.245
Authors: S Caritis; B Sibai; J Hauth; M D Lindheimer; M Klebanoff; E Thom; P VanDorsten; M Landon; R Paul; M Miodovnik; P Meis; G Thurnau Journal: N Engl J Med Date: 1998-03-12 Impact factor: 91.245
Authors: Ali S Khashan; Marie Evans; Marius Kublickas; Fergus P McCarthy; Louise C Kenny; Peter Stenvinkel; Tony Fitzgerald; Karolina Kublickiene Journal: PLoS Med Date: 2019-07-30 Impact factor: 11.069